Vacuum assisted Biopsy Devices Sales

Vacuum Assisted Biopsy Devices Sales Market Outlook

The global vacuum assisted biopsy devices market is anticipated to reach approximately USD 1.5 billion by 2035, growing at a remarkable CAGR of around 6.5% during the forecast period from 2025 to 2035. This robust growth is primarily driven by the increasing prevalence of cancer, particularly breast and lung cancers, which necessitates early and accurate diagnostic methods. Moreover, advancements in technology, such as the development of automated systems that enhance the precision and efficiency of biopsies, are significantly contributing to market expansion. Additionally, the growing geriatric population and rising health awareness are leading to a higher demand for minimally invasive procedures, providing further impetus for the vacuum assisted biopsy devices market. Rising investments in healthcare infrastructure and increasing adoption of outpatient surgical procedures are also crucial factors propelling market growth.

Growth Factor of the Market

The growth of the vacuum assisted biopsy devices market is strongly linked to the rising prevalence of various types of cancers, particularly breast cancer, which has become one of the leading causes of cancer-related deaths globally. This alarming statistic is prompting healthcare providers to employ more sophisticated diagnostic techniques, such as vacuum-assisted biopsy (VAB), which are less invasive and allow for faster recovery times. Furthermore, technological advancements, including the integration of imaging techniques such as ultrasound and MRI with biopsy procedures, are enhancing the accuracy and effectiveness of cancer diagnosis, thus driving the demand for these devices. Additionally, the increased focus on patient comfort and the need for efficient diagnostic methods are propelling the uptake of vacuum assisted biopsy devices. As healthcare systems worldwide evolve, the shift toward outpatient settings for surgical procedures is creating a conducive environment for the growth of the vacuum assisted biopsy devices market.

Key Highlights of the Market

• The vacuum assisted biopsy devices market is projected to grow at a CAGR of 6.5% from 2025 to 2035.
• Technological advancements in device design and functionality are enhancing diagnostic accuracy.
• Increased prevalence of cancer is driving the demand for effective and minimally invasive biopsy techniques.
• The rise of outpatient procedures is creating new opportunities for market growth.
• North America is expected to remain a key market contributor due to advanced healthcare infrastructure.

By Product Type

Automated Vacuum Assisted Biopsy Devices:

Automated vacuum assisted biopsy devices are notable for their efficiency and precision, making them a favored choice among healthcare professionals. These devices allow for rapid collection of tissue samples, significantly reducing the time and discomfort for patients. With advanced features such as automatic sample collection and real-time imaging integration, these devices enhance the accuracy of the biopsy process. The automation aspect minimizes human error, ensuring more reliable results, which is particularly crucial in oncology. As a result, this segment is witnessing a steady growth rate as healthcare providers increasingly adopt these technologies to improve patient outcomes and streamline clinical workflows.

Semi-Automated Vacuum Assisted Biopsy Devices:

Semi-automated vacuum assisted biopsy devices serve as a bridge between manual and fully automated options. These devices require some degree of operator intervention while still providing enhanced efficiency compared to traditional manual methods. They are designed to optimize the biopsy procedure by facilitating easier tissue sample retrieval and minimizing patient discomfort. This segment is particularly attractive to clinics and healthcare facilities looking for cost-effective solutions without compromising on diagnostic quality. As more practitioners seek to balance automation with hands-on control, the demand for semi-automated devices is expected to grow steadily in the coming years, especially in smaller medical settings.

Manual Vacuum Assisted Biopsy Devices:

Despite the rise of automation in medical devices, manual vacuum assisted biopsy devices continue to hold relevance in the market. These devices offer simplicity and ease of use, making them ideal for specific applications where precision is not as critical or when resources are limited. They are often used in smaller clinics or rural healthcare facilities where advanced technologies may not be readily available. The manual operation allows healthcare providers to maintain a hands-on approach, which can be advantageous in certain clinical scenarios. However, the growth of this segment is anticipated to be slower compared to its automated and semi-automated counterparts, as the overall trend in the industry leans toward automation and enhanced efficiency.

By Application

Breast Biopsy:

Breast biopsy is one of the most prevalent applications for vacuum assisted biopsy devices, primarily due to the high incidence of breast cancer. These devices are instrumental in obtaining tissue samples for diagnosis, allowing for precise targeting of suspicious lesions detected through imaging techniques. The growing awareness of breast cancer and the importance of early detection have led to an increase in the number of biopsies performed, thereby driving the demand for vacuum assisted biopsy devices in this segment. As healthcare facilities strive to improve patient outcomes through early intervention, the breast biopsy application is expected to continue leading the market.

Lung Biopsy:

Lung biopsy procedures are crucial for the diagnosis of lung cancer and other pulmonary conditions. Vacuum assisted biopsy devices provide an effective means of obtaining lung tissue samples, particularly in cases where traditional biopsy methods may be more invasive or less accurate. The increasing prevalence of lung cancer, exacerbated by factors such as smoking and environmental pollutants, is significantly boosting the demand for lung biopsy procedures. As a result, the application of vacuum assisted biopsy devices in lung biopsies is projected to grow, supported by advancements in imaging technologies that facilitate more precise targeting during the biopsy process.

Prostate Biopsy:

The application of vacuum assisted biopsy devices in prostate biopsies is gaining traction due to the rising cases of prostate cancer. These devices enhance the ability to collect multiple samples in a single procedure, minimizing patient discomfort and ensuring comprehensive analysis. The increasing adoption of targeted biopsy techniques, which utilize imaging guidance, is further propelling the use of vacuum assisted devices in this application. As prostate cancer remains one of the most diagnosed cancers among men, the demand for efficient biopsy solutions is expected to rise, fostering growth in this segment of the market.

Liver Biopsy:

Liver biopsy is critical for diagnosing various liver diseases, including cirrhosis and hepatitis. Vacuum assisted biopsy devices offer a minimally invasive approach, allowing for efficient sample collection with reduced patient recovery time. The growing prevalence of liver diseases, driven by factors such as obesity and viral infections, is propelling the demand for effective diagnostic methods, including liver biopsies. As healthcare providers aim to deliver better patient care through timely diagnosis, the application of vacuum assisted biopsy devices in liver procedures is likely to witness significant growth, highlighting the importance of these technologies in managing liver health.

Others:

The "Others" category encompasses various biopsy applications that utilize vacuum assisted devices, extending beyond the traditional cancer diagnoses. This includes biopsies for rare tumors and other medical conditions where tissue analysis is essential. The versatility of vacuum assisted biopsy devices allows for their application in various procedures, which is increasingly recognized by healthcare practitioners. This segment is expected to expand as awareness grows regarding the benefits of minimally invasive biopsy techniques across a broader range of medical scenarios. As innovations continue to emerge in biopsy technologies, the potential applications for vacuum assisted devices will likely increase.

By Distribution Channel

Hospitals:

Hospitals represent a significant distribution channel for vacuum assisted biopsy devices, as they often house specialized departments for oncology and radiology. The advanced infrastructure and availability of skilled personnel in hospitals facilitate the adoption of these devices, enabling them to perform a high volume of biopsies. Hospitals are increasingly investing in state-of-the-art technologies to enhance patient care and improve diagnostic accuracy. As a result, the demand for vacuum assisted biopsy devices in hospitals is expected to remain robust, driven by the need for efficient, reliable, and minimally invasive biopsy solutions.

Diagnostic Centers:

Diagnostic centers play a crucial role in the distribution of vacuum assisted biopsy devices, specializing in providing advanced diagnostic services. These facilities often utilize cutting-edge technologies to perform a variety of diagnostic tests, including biopsies. The increasing demand for accurate and timely diagnoses has led to the proliferation of diagnostic centers, driving the need for efficient biopsy solutions. The convenience and accessibility offered by these centers make them a vital channel for vacuum assisted biopsy devices, as patients seek faster diagnostic services without the need for hospitalization. This segment is poised for growth, as healthcare providers continue to prioritize diagnostic excellence.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming an increasingly popular distribution channel for vacuum assisted biopsy devices due to the rising trend of outpatient procedures. These centers provide a cost-effective alternative to traditional hospital settings, allowing for same-day discharge and minimal recovery time for patients. The adoption of vacuum assisted biopsy devices in ASCs is being driven by the need for efficient, less invasive diagnostic solutions that can be performed in an outpatient setting. As patient preferences shift towards convenience and affordability, the role of ASCs in the vacuum assisted biopsy devices market is expected to grow, aligning with broader trends in healthcare delivery.

Others:

The "Others" category includes various distribution channels such as specialty clinics, research institutions, and online platforms. Specialty clinics often focus on specific areas of healthcare, such as oncology or radiology, and may utilize vacuum assisted biopsy devices to deliver targeted diagnostic services. Additionally, research institutions engaged in clinical studies may also be significant customers for these devices. The rise of e-commerce in the medical sector allows providers to reach a wider audience, making vacuum assisted biopsy devices more accessible. This diverse array of distribution channels supports the overall growth of the market and enhances the visibility of vacuum assisted biopsy technologies.

By User

Hospitals:

Hospitals are among the primary users of vacuum assisted biopsy devices, as they often have specialized departments for diagnostics and oncology. The need for accurate and efficient tissue sampling in an acute care setting drives hospitals to invest in advanced biopsy technologies. With increasing case loads of cancer patients, hospitals are adopting vacuum assisted devices to streamline their biopsy processes and enhance patient outcomes. Furthermore, hospitals are more likely to stay updated with the latest technologies, ensuring they provide the highest standards of care. This consistent demand positions hospitals as a key user segment in the vacuum assisted biopsy devices market.

Clinics:

Clinics, including outpatient and specialty practices, are increasingly utilizing vacuum assisted biopsy devices to offer patients timely and efficient diagnostic services. These facilities value the reduced recovery time and lower complication rates associated with minimally invasive procedures. Clinics often prioritize cost-effective solutions while ensuring quality care, making vacuum assisted biopsy devices an attractive option. With the growing emphasis on preventive healthcare and early cancer detection, clinics are likely to expand their biopsy offerings, thereby driving demand for these devices in a clinical setting. This trend reflects the evolving landscape of healthcare delivery and the growing acceptance of outpatient diagnostic procedures.

Diagnostic Centers:

Diagnostic centers are integral users of vacuum assisted biopsy devices, focusing solely on providing high-quality diagnostic services. These centers leverage the precision of vacuum assisted techniques to perform various biopsies, catering to a diverse patient population. With a growing emphasis on early cancer detection and accurate tissue diagnosis, diagnostic centers are increasingly adopting advanced biopsy technologies. The competitive landscape among diagnostic centers also ensures they remain at the forefront of technological advancements, driving demand for vacuum assisted biopsy devices. As patients seek specialized diagnostic services, the reliance on these devices in diagnostic centers is set to grow significantly.

Others:

The "Others" category encompasses diverse users of vacuum assisted biopsy devices, including research facilities and educational institutions. Research institutions may employ these devices for clinical trials and studies aimed at improving biopsy techniques or developing new diagnostic methods. Educational institutions that train medical professionals also utilize these devices for hands-on learning experiences. Additionally, emerging telemedicine practices may explore remote biopsy applications, further diversifying the user base. As the healthcare landscape evolves, the potential user categories for vacuum assisted biopsy devices will likely broaden, creating more opportunities for growth in this market.

By Region

The North American region holds a dominant position in the vacuum assisted biopsy devices market, accounting for approximately 40% of the global market share. The presence of advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and significant investments in cancer research are key contributors to this dominance. The North American market is expected to grow at a CAGR of 7% during the forecast period, driven by the increasing prevalence of breast and lung cancers. Moreover, a growing emphasis on early diagnosis and patient-centric care further bolsters the demand for vacuum assisted biopsy devices in this region. As healthcare providers continue to prioritize effective biopsy solutions, North America is expected to remain a crucial player in the market.

Europe is another significant region in the vacuum assisted biopsy devices market, representing around 25% of the total market share. A well-established healthcare system, coupled with increasing awareness about cancer prevalence and the importance of early detection, is driving the demand for these devices. The market in Europe is projected to grow at a CAGR of 6% from 2025 to 2035, with countries like Germany, France, and the UK leading the charge in terms of adoption. Moreover, the European market is witnessing a rise in outpatient procedures, further enhancing the demand for minimally invasive biopsy techniques. As healthcare authorities prioritize innovative diagnostic solutions, the vacuum assisted biopsy devices market in Europe is poised for substantial growth.

Opportunities

The vacuum assisted biopsy devices market is witnessing numerous opportunities as healthcare providers increasingly prioritize early cancer detection and minimally invasive procedures. With the rising prevalence of cancers, especially breast and lung cancers, there is a growing demand for efficient and effective biopsy solutions. Manufacturers have the opportunity to innovate and develop advanced technologies, such as integrating imaging modalities with biopsy devices to improve accuracy and precision. Additionally, expanding into emerging markets where healthcare infrastructure is evolving presents a significant growth opportunity for companies. As patient preferences shift towards outpatient settings and faster recovery times, there is a clear path for vacuum assisted biopsy devices to gain traction in various healthcare settings. Overall, these opportunities highlight the potential for substantial market growth and innovation in the coming years.

Another promising opportunity lies in the increasing focus on personalized medicine and targeted therapies. As patients become more involved in their healthcare decisions, there is a growing demand for diagnostic procedures that provide specific information to tailor treatment plans. Vacuum assisted biopsy devices can play a critical role in this context, offering precise tissue sampling that informs treatment strategies. Furthermore, collaborations between device manufacturers and healthcare facilities can enhance the development and adoption of new technologies, ensuring that professionals have access to the latest innovations. The continuous evolution of telehealth and remote patient monitoring also presents avenues for integrating vacuum assisted biopsy devices into comprehensive care strategies. This convergence of technology and patient care is expected to propel market growth and open new avenues for innovation.

Threats

Despite the promising prospects of the vacuum assisted biopsy devices market, several threats could hinder its growth. One significant threat is the potential for economic downturns that could lead to reduced healthcare budgets and spending on advanced medical technologies. In times of financial uncertainty, healthcare providers may prioritize essential services over investments in new equipment, limiting the market for vacuum assisted biopsy devices. Additionally, the presence of alternative diagnostic methods, such as liquid biopsies and imaging techniques, poses a challenge to the traditional biopsy market. As these alternatives gain traction, there may be a shift in preference away from invasive procedures, impacting the demand for vacuum assisted devices.

Another key concern for the vacuum assisted biopsy devices market is the regulatory landscape and potential compliance challenges. The medical device industry is subject to stringent regulations to ensure safety and efficacy, and any changes in regulatory requirements could affect the speed of product development and market entry. Furthermore, the market is characterized by intense competition, with numerous players striving to innovate and capture market share. This competitive pressure can lead to pricing wars and reduced profit margins, posing a threat to smaller companies and startups entering the space. Overall, addressing these threats will be crucial for maintaining a stable growth trajectory in the vacuum assisted biopsy devices market.

Competitor Outlook

• Hologic, Inc.
• Bard Biopsy Systems (BD)
• Syneron Candela
• Medtronic plc
• Cook Medical LLC
• Siemens Healthineers
• Johnson & Johnson
• Fujifilm Holdings Corporation
• GE Healthcare
• Olympus Corporation
• Canon Medical Systems Corporation
• Koninklijke Philips N.V.
• Intermountain Healthcare
• Boston Scientific Corporation
• Neusoft Medical Systems Co., Ltd.

The competitive landscape of the vacuum assisted biopsy devices market is characterized by a mix of established players and emerging companies striving to capture market share through innovation and advanced technologies. Major companies like Hologic, Inc., and Bard Biopsy Systems (BD) dominate the market due to their extensive product offerings, strong brand presence, and proven track records in the medical device industry. These companies continually invest in research and development to enhance their product lines and maintain their competitive edge. Additionally, partnerships and collaborations with healthcare providers and research institutions are common strategies employed to expand their market reach and improve product efficacy.

Another noteworthy competitor in the market is Medtronic plc, which has made significant strides in the vacuum assisted biopsy segment with its advanced imaging integration and automation capabilities. The presence of large multinational corporations like Siemens Healthineers and GE Healthcare further intensifies the competition, as these companies leverage their vast resources and technological expertise to develop cutting-edge biopsy solutions. Moreover, smaller, innovative companies are entering the market, focusing on niche applications and specialized products, contributing to a dynamic competitive environment. This influx of new entrants fosters innovation and drives advancements in biopsy technologies, ultimately benefiting healthcare providers and patients.

Key players such as Cook Medical and Olympus Corporation are also making significant contributions to the market by offering a range of vacuum assisted biopsy devices tailored for specific applications. These companies frequently participate in trade shows and industry events to showcase their latest innovations and deepen relationships with healthcare professionals. Furthermore, the increasing emphasis on personalized medicine and targeted therapies is influencing the competitive strategies of these companies, prompting them to develop solutions that cater to the evolving needs of the healthcare landscape. As the market continues to grow and evolve, the competitive dynamics will undoubtedly shift, presenting both challenges and opportunities for existing and new players alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GE Healthcare
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Syneron Candela
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Cook Medical LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Olympus Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Bard Biopsy Systems (BD)
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Intermountain Healthcare
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Koninklijke Philips N.V.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fujifilm Holdings Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Canon Medical Systems Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Neusoft Medical Systems Co., Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Vacuum assisted Biopsy Devices Sales Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Diagnostic Centers
    • 6.1.4 Others
  • 6.2 Vacuum assisted Biopsy Devices Sales Market, By Application
    • 6.2.1 Breast Biopsy
    • 6.2.2 Lung Biopsy
    • 6.2.3 Prostate Biopsy
    • 6.2.4 Liver Biopsy
    • 6.2.5 Others
  • 6.3 Vacuum assisted Biopsy Devices Sales Market, By Product Type
    • 6.3.1 Automated Vacuum Assisted Biopsy Devices
    • 6.3.2 Semi-Automated Vacuum Assisted Biopsy Devices
    • 6.3.3 Manual Vacuum Assisted Biopsy Devices
  • 6.4 Vacuum assisted Biopsy Devices Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Centers
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Vacuum assisted Biopsy Devices Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Vacuum assisted Biopsy Devices Sales market is categorized based on

By Product Type

• Automated Vacuum Assisted Biopsy Devices
• Semi-Automated Vacuum Assisted Biopsy Devices
• Manual Vacuum Assisted Biopsy Devices

By Application

• Breast Biopsy
• Lung Biopsy
• Prostate Biopsy
• Liver Biopsy
• Others

By Distribution Channel

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others

By User

• Hospitals
• Clinics
• Diagnostic Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hologic, Inc.
• Bard Biopsy Systems (BD)
• Syneron Candela
• Medtronic plc
• Cook Medical LLC
• Siemens Healthineers
• Johnson & Johnson
• Fujifilm Holdings Corporation
• GE Healthcare
• Olympus Corporation
• Canon Medical Systems Corporation
• Koninklijke Philips N.V.
• Intermountain Healthcare
• Boston Scientific Corporation
• Neusoft Medical Systems Co., Ltd.